Seven out of 29 patients with metastatic renal cell carcinoma (RCC) considered eligible for allogeneic stem cell transplantation underwent nonmyeloablative stem cell transplantation (NST) from HLA-identical donors. Conditioning comprised cyclophosphamide, fludarabine and antithymocyte globulin. Prolonged mixed chimerism (MC) after engraftment converted to complete donor chimerism (CC) after infusion of donor lymphocytes and/or graft-versus-host disease (GvHD) in six patients. Five patients developed severe GvHD. Two of seven patients had a delayed tumor response after conversion to CC. After a median follow-up of 10 months (4-24 months), 5/7 patients are alive, one in very good partial remission (PR), one with stable and three with progressive disease. One of the seven patients died from sepsis in PR and 1/7 died from rapid tumor progression after sustained MC. None of the 22 nontransplanted patients responded to further therapies. Survival after 1 year was 59% in transplanted and 66% in nontransplanted patients (n.s.). A pooled data analysis from the literature suggests a graft-versus-tumor effect after transplant in patients with metastatic RCC, which becomes effective after chimerism conversion. Available data demonstrate high nonrelapse mortality in these patients. NST in RCC still has to be regarded as an investigational approach requiring careful patients' selection and longer follow-up within clinical studies. Metastatic refractory renal cell carcinoma (RCC) has a dismal prognosis because of the tumor's intrinsic resistance to conventional chemotherapy.
tive stem cell transplantation (NST); mixed chimerism (MC); graft-versus-host disease (GvHD) Metastatic refractory renal cell carcinoma (RCC) has a dismal prognosis because of the tumor's intrinsic resistance to conventional chemotherapy. 1 The tumor's immunologic properties have made advanced RCC a target for experimental therapies. [2] [3] [4] Response rates to chemoimmunotherapy are limited with only minor prolongation of overall survival. 5 Nonmyeloablative stem cell transplantation (NST) for refractory RCC is currently under clinical investigation trying to exploit a graft-versus-tumor (GvT) effect. 6 Donor T lymphocytes are regarded as major effector cells of the GvT effect after allogeneic stem cell transplantation (SCT), which can be deduced from a higher relapse rate after T-cell depleted SCT 7 and the successful reinduction of remissions in relapsing malignancies after allogeneic SCT through infusions of donor lymphocytes (DLI). 8 A GvT effect is considered to be responsible for the survival advantage of allogeneic SCT over other therapies in hematologic malignancies. 7 However, considerable nonrelapse mortality (NRM) after high-dose radio-and chemotherapy has restricted allogeneic SCT to younger patients without comorbidity. The development of reduced intensity conditioning regimens for NST has led to a reduction of NRM in malignant hematologic disease and extended the indication for allogeneic SCT to older and heavily pretreated patients. [9] [10] [11] [12] In NST, preparative regimens mainly aim at adequate immunosuppression for stable donor cell engraftment in contrast to the cytoreductive effect of high-dose conditioning. The GvT effect is thought to be exerted by engrafting allogeneic lymphocytes given at the time of transplantation or later through DLI. 13 A first study on NST and DLI in 19 patients with metastatic RCC has resulted in a promising tumor response rate of more than 50% of the patients with a median follow-up of only 10 months. The development of GvHD was associated with tumor regression, which supports a GvT effect. 6 More recent studies have reported conflicting results and durable tumor responses after NST seem to be a rare event. [14] [15] [16] We report on our experience with NST in patients with metastatic RCC, who had tumor progression after chemoimmunotherapy and were considered eligible for NST. Delayed and sustained tumor responses occurred concurrent with lymphoid donor cell engraftment, which is compatible with a GvT effect. Considerable toxicity in these mostly elderly patients led to prolonged hospital stays and NRM. We compared the outcomes of transplanted and nontransplanted patients in the eligible patients. Data from these patients as well as an analysis of the published literature demonstrates a close association of GvHD and GvT response, but also high morbidity and mortality of NST requiring careful patient selection.
Patients and methods

Patients' characteristics
Between December 2000 and June 2003, 29 patients with metastatic RCC presenting to the Department of Urology were considered eligible for allogeneic SCT according to the protocol. Eligibility criteria comprised patients between 18 and 65 years biological age with metastatic RCC not amenable to surgical therapy and a failure of immunotherapy. Patients with cerebral metastases and those with bone metastases as the sole tumor manifestation were excluded. Measurable clinical or radiological manifestation of disease was required. Performance status had to be 0-2. Eligible patients were required to have an HLA-identical donor.
All 29 patients had their primary tumor resected irrespective of the existence of metastases at that time. Median time from primary diagnosis to metastatic disease was 2 years. All patients had received several cycles of chemoimmunotherapy consisting of high-dose interleukin 2 and interferon alpha75-fluorouracil or 13-cis retinoic acid. Serologic HLA class I and molecular class II typing identified HLA-compatible donors in 14/29 patients; 13/29 had related donors, from which 11/13 were HLAidentical and 2/13 had one class I mismatch; an unrelated donor was identified in a 25-year-old patient. Seven of 14 patients with HLA-compatible donors did not undergo allogeneic SCT because of rapid disease progression in five, bad general condition in one and refusal in one patient. Of 29 patients, 15 had no HLA-compatible donor ( Table 1) .
Seven of these 29 patients underwent NST in the Department of Hematology and Oncology between June 2001 and March 2003. The median age was 58 years (range 25-64 years), five were male and two were female subjects. Three out of seven patients had metastatic disease at diagnosis; in the other four patients, time from diagnosis to systemic tumor spread was 1-5 years. Five of seven patients had a clear-cell type tumor. All patients had radiologically measurable disease (Table 2) .
Patients gave written informed consent. The study protocol was reviewed and approved by the ethical committee of the University Hospital Charite´and was in accordance with the Helsinki declaration.
NST and DLI
Conditioning therapy was performed with cyclophosphamide 60 mg/kg body weight (bw) i.v. days -7 and -6 (total dose 120 mg/kg bw), fludarabine 25 mg/m 2 i.v. days -5 till -1 (total dose 125 mg/m 2 ) and antithymocyte globulin (ATG) (Fresenius) 10 mg/kg bw i.v. days -3 till -1 (total dose 30 mg/kg). 6 Patients were transplanted with G-CSFmobilized peripheral blood stem cells from HLA-identical related (n ¼ 6) or unrelated (n ¼ 1) donors. GvHD prophylaxis was performed with cyclosporine A (CSA) 2 Â 2.5 mg/ kg i.v. started on day -1 and tapered after 6-8 weeks, if no GvHD had developed. After transplantation from an unrelated donor, patient no. 7 received CSA plus mycophenolate mofetil (MMF) 3 Â 1 g i.v. from the day of NST until day þ 28. Acute and chronic GvHD were evaluated using established criteria. 17, 18 DLI were planned to be given after day þ 60, if no GvHD had developed after discontinuation of CSA and MMF and mixed chimerism (MC) persisted. DLI were given in escalating doses every 4 weeks starting with 5 Â 10 6 CD3 þ cells/kg bw, then 1 Â 10 7 and 5 Â 10 7 as available.
Infection prophylaxis
NST were performed in laminar air flow rooms; infection prophylaxis and antimicrobial therapy were performed according to institutional standards for allogeneic SCT. In short, selective gut decontamination consisted of oral ciprofloxacin 2 Â 500 mg/day and amphotericin B suspension 4 Â 1 ml/day. Cotrimoxazol 960 mg was given as pneumocystis carinii prophylaxis thrice weekly 2 weeks before NST and started again on day þ 28 until day þ 150; pentamidine inhalations were given in case of renal insufficiency. Acyclovir 3 Â 5 mg/kg/day i.v. was given until neutrophil count exceeded 1.0/nl. Immunoglobulins (10 g) were administered i.v. every 2 weeks for 6 weeks and repeated, if total IgG level was below 5 g/l. Weekly blood testing was performed for cytomegalovirus (CMV)-DNA and -antigen pp65 until dismissal and on days þ 90, þ 180 and þ 360 after transplantation. CMV-negative blood products were provided for CMV-seronegative recipientdonor constellations. Patients were transfused with leukocyte-depleted and irradiated blood products.
Engraftment, chimerism analysis and tumor response
For demonstration of engraftment, neutrophil counts had to be above 0.5/nl and platelet counts above 20/nl for 3 days without transfusional support. Chimerism analysis from peripheral leukocyte subpopulations were performed by a multiplex-STR assay as described recently. 19 Briefly, blood samples were collected from donor and recipient before transplant and were sorted with antibody coated Dynabeads (Deutsche Dynal GmbH, Hamburg, Germany) against CD4, CD8 and CD3. The purity of the specific lineages was controlled by FACS analysis after detaching the beads at different stages (Becton Dickinson, Heidelberg, Germany) and was determined to be more than 93%.
Genomic DNA was extracted from sorted blood samples using standard procedures. 20 DNA was also prepared using silica membranes (Qiamp Blood Kit, Qiagen, Hilden, Germany). Prior to STR amplification, all DNA samples were quantitated and diluted to optimal working concentrations.
STR polymorphisms were analyzed on ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems, Darmstadt, Germany) after coamplification of nine STRs with the AmpFlSTR Profilerplus Kit (PE Applied Biosystems, Darmstadt, Germany). 19 We determined the ratio of donor and recipient cells by calculating the proportion of the peak areas of donor and recipient signals. The estimated detection limit for the AmpFlSTR Profilerplus multiplex system is about 5% for the minor component in a mixed sample. A minimum total number of 1000 cells has been regarded sufficient for conclusive analysis. 19 Samples were excluded from the analysis, when no unequivocal donor or recipient profile was detected.
MC was defined as 5% or more recipient cells in at least one leukocyte subpopulation-specific analysis in peripheral blood in two independent analyses after hematopoietic reconstitution. 12 Chimerism analyses from peripheral blood were performed after 2 weeks, monthly until 6 months, bimonthly until 1 year after NST and then every 3 months.
Tumor response was evaluated clinically and by lung or abdominal computed tomography (CT) scan before NST and every 3 months after NST.
Statistical analysis
Statistical analysis of the patients considered eligible for NST and pooled data from the literature was performed using SPSS 11.0 (Statistical Package for the Social Science) for Windows. Results are given with median and range. Owing to the limited sample sizes and/or skew distributions in interesting variables, groups of individuals were compared using nonparametric statistical tests (Mann-Whitney U-test for two independent groups). The relationships between tumor response and GvHD, number of involved organs, therapies prior to NST and histopathology were evaluated using Fisher's exact test and the exact w 2 test, respectively. Survival data were analyzed according to Kaplan-Meier and tested univariately with the log-rank test. 21 Significance was assessed at the Po0.05 level, twosided.
Results
Engraftment
The median number of CD34 þ cells was 5.9 Â 10 6 per kg bw (range 3.5-10.7) in these seven patients and all engrafted. The median time to absolute neutrophil count 40.5/nl was 11 days (8-14) and 6 days (0-14) to platelet recovery above 20/nl, three patients never had platelets below 20/nl. Patients received a median of 6 red blood cell (RBC) units (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) ; only two patients required 3 and 9 platelet concentrates, respectively.
After withdrawal of CSA, DLI were given to 4/7 patients, 2/4 received one dose and 2/4 received two doses. DLI were given between day þ 51 and þ 150. DLI were administered before day þ 60 in patient 3, because of a decrease of donor T cells. All patients had MC before first DLI. Three of seven patients received no DLI, because of early GvHD in 2/7 and rapid clinical deterioration because of progressive disease (PD) in 1/7.
Donor cell engraftment was delayed. More than 50% lymphoid donor cells were observed 42-153 days (median 103 days) after NST. The median number of CD3 þ donor cells 30, 60, 100 and 180 days after NST was 43% (range 17-80%), 76% (25-89%), 80% (58-100%) and 100% (97-100%) respectively (Figure 1 ). CD4 þ and CD8 þ donor cells had similar engraftment kinetics at the same time points.
Persistent complete donor chimerism (CC) was finally reached in 6/7 patients, all four patients, who received DLI, rapidly converted from MC to CC throughout all lymphoid and myeloid cell subpopulations, two patients without DLI reached CC after development of GvHD. One of seven patients had persistent mixed MC until day þ 100, recipient cells increased afterwards with simultaneous rapid tumor progression.
Transplant-related toxicity
Two patients had transient fever during infusion of ATG, which was treated with glucocorticoids. Three patients developed CMV reactivation and were treated with ganciclovir until CMV-PCR became negative. One of them presented with pancytopenia, which resolved during antiviral therapy. The other two patients had no symptoms of viral infection. Two patients had local catheter-related infection without signs of systemic disease. Three patients had no fever or signs of infection. Mucositis 4I1 was not observed and none of the patients required parenteral nutrition.
Two patients had a generalized cerebral seizure on day þ 14 and day þ 184, respectively. Cranial CT-and MRI scan revealed bilateral posterior large hyperintense lesions resembling ischemia in one of them. This patient rapidly developed tetraparesis, which slowly regressed only after withdrawal of CSA. Mental confusion in another patient led to neuroradiologic evaluation, also revealing extended bilateral hyperintense regions resembling leukoencephalopathy. After termination of CSA, slow as yet incomplete improvement occurred and posterior reversible encephalopathy syndrome (PRES) due to CSA was considered the most likely diagnosis in both patients. 22 Acute and/or chronic GvHD developed in 5/7 patients and required immunosuppressive therapy. Three of five patients had acute GvHD grade I-II early after hematopoietic engraftment (n ¼ 2) or after first DLI (n ¼ 1), from which two progressed to chronic extensive GvHD requiring prolonged hospital stays. Chronic GvHD developed in two more patients after DLI. One of them was admitted with late onset GvHD of skin, liver and gut; acute immunohemolytic anemia and idiopathic thrombocytopenic purpura (Evans syndrome) additionally developed requiring RBC-transfusions. All signs of chronic GvHD resolved under immunosuppressive therapy. One patient presented with fever and pancytopenia after DLI. Bone marrow aspiration showed aplastic bone marrow. Circulating cells were all donor. The patient was treated with G-CSF for a prolonged time with only minor response. He developed sepsis and died on day þ 194 due to sepsis (Table 3) .
Outcome
Four out of seven patients had no response to NST and one out of four has died from tumor progression with a concurrent increase of recipient cells. One of seven has stable disease (SD) 6 months after NST. Very good partial remission (PR) was achieved in 1/7 patients after 4 months developing together with severe chronic GVHD. By now, GvHD is controlled and the patient is free of tumor progression for more than 20 months after NST. Histologic confirmation of remission has not been performed (Figure 2 ). Another patient reached PR 6 months after NST without GvHD, but died shortly afterwards from infectious complications.
After a median follow-up of 10 months (range 4-24 months), 1/7 patients has died from PD 141 days after NST. One patient died in PR from sepsis 194 days after NST. Five out of seven patients (71%) are alive, one in very good PR, one with SD and three with PD (Table 3) .
A total of 22 patients, who were initially considered eligible for allogeneic SCT, did not undergo NST. They received one or several other therapies after exclusion from NST, namely chemo-and/or immunotherapy (n ¼ 11), radiotherapy (n ¼ 5), surgery (n ¼ 3), mistletoe (n ¼ 7), tumor vaccination (n ¼ 1), or no further therapy (n ¼ 5). After a median follow-up of 14 months (range 1-31 months), 11/22 have died from PD and 11/22 patients are alive, 5/11 in PD, 5/11 in SD and 1/11 is lost to follow-up. No CR or PR was observed in these patients. In univariate analysis, survival at 1 year is 59% for transplanted and 67% for nontransplanted patients (P ¼ 0.256) (Figure 3 ).
Discussion
New therapeutic approaches in metastatic RCC are required because RCC is resistant to systemic chemotherapy. 1 Combination chemoimmunotherapy has resulted in response rates between 10 and 40%. However, CR are very rare and 5-year survival rates range from below 5 to 25%. 5 NST has been investigated in smaller series of patients with metastatic RCC and has induced sustained tumor regressions in a few of them. 6, [14] [15] [16] [23] [24] [25] Our results confirm the feasibility and efficacy of NST in patients with metastatic RCC refractory to chemoimmunotherapy. The prolonged MC we observed fits well into the concept of NST. Since recipient immunity is not fully ablated, a higher rate of initial MC ensues. 13 Prolonged MC paralleled delayed tumor response after NST. Tumor responses were observed 3 months and later after transplantation. At the time of radiologically proven tumor response, donor T lymphocytes had become predominant in chimerism analysis. Conversion to CC was reinforced by DLI in four patients and onset of GvHD in two patients following the termination of immunosuppression. Experimental data showed that the interaction of donor T cells with host antigen-presenting cells in MC is critical for the development of GvHD 26 and DLI-mediated GvT effect in MC. 27 DLI have induced CR in various relapsing malignant hematologic and oncologic diseases, which occurred concurrently with the conversion of MC to CC. 8, 12, 13, 28 The simultaneous occurrence of chimerism conversion and tumor response after DLI or withdrawal of immunosuppression also observed by others strongly supports a GvT effect in RCC and underlines the importance of sustained donor cell engraftment as a prerequisite for an immunologic antitumor effect. 6, 13, 28 Fully published data on NST in metastatic RCC from seven other studies comprise 95 patients. 6, [14] [15] [16] [23] [24] [25] The primary tumor was resected at diagnosis in almost all patients, because nephrectomized patients with metastatic RCC have a superior response and survival following interferon alpha therapy. 29 Most of the patients had received several different therapies before NST including surgery, immunotherapy, radiotherapy, chemotherapy and laser-induced thermotherapy. More than 90% of the patients reported in the literature had been treated with immunotherapy before transplant and had progressed.
Most patients had received fludarabine and/or cyclophosphamide before transplantation and were transplanted from HLA-identical siblings. Only six patients had an unrelated matched donor, and three had a mismatched donor. 6, 23, 24 Adequate immunosuppression of the various conditioning regimens is indicated by an engraftment rate of over 90%. Three patients failed to engraft in one study leading to a dose intensification of the conditioning regimen. 16 ATG, which was added by us and others to the conditioning No regimen, is probably dispensable to ensure stable engraftment, but conditioning regimens are too heterogeneous and studies too small to draw further conclusions.
Rates of GvHD varied considerably between the publications and ranged from 0-86% for acute and 22-71% for chronic GvHD (Table 4) . Differences in patients' ages, GvHD prophylaxis and follow-up as well as the small number of patients in single studies may well account for these diversities. Pooled data however confirm the high rate of acute and chronic GvHD observed in the first series of patients by Childs et al 6 and can be explained by the premature withdrawal of GvHD prophylaxis in most of the studies including our own because of early tumor progression or persistent MC. Withdrawal of immunosuppressive drugs was frequently followed by severe GvHD. In other patients, DLI were administered early thriving at conversion into CC and triggering of a GvT effect analogous to published results on CML and other hematologic malignancies. 8, 13 Tumor response is evaluable in 91/95 patients; CR were observed in eight (8%) and PR in 16 out of 95 patients (17%) for an overall tumor response rate of 25% (Table 5) . Maximum tumor responses mostly occurred between 90 and 240 days after NST. Pooled data of these small studies strongly support a GvT effect in RCC transmitted by GvHD, because 22/24 responding patients 6, [14] [15] [16] [23] [24] [25] as well as one of our responding patients had developed acute or chronic GvHD or both. While GvHD compared with no GvHD seems to be a prerequisite for tumor response (Po0.001), it does not on the other hand protect from tumor progression, as 19/44 nonresponders 6, [14] [15] [16] 23, 24 were reported to have acute or chronic GvHD. Two patients from the literature and one of ours had tumor regression without clinical GvHD, 6, 24 suggesting that a GvT effect after NST might be operative without obvious GvHD. Potential tumor-restricted antigens and MHC class Irestricted T-cell clones with tumor-specific cytotoxicity are currently being pursued. 30 Number of involved organs by metastatic tumor spread (P ¼ 0.078), pathologic subtype (clear-cell vs non-clear-cell subtype) (P ¼ 0.062) and number of prior therapies (P ¼ 0.805) had no significant impact on tumor response in pooled analysis. The expectation from reduced intensity conditioning was a lowering of transplant-related toxicity compared to standard high-dose conditioning. However, NRM affected 14/70 patients (20%) mostly caused by infections and GvHD (Table 5) . One of our patients also succumbed to sepsis after DLI, which was followed by pancytopenia. Additionally, CSA neurotoxicity was of special concern in our elderly patients being the most likely diagnosis in three patients with seizure, tetraparesis and mental confusion after exclusion of other possible causes. CSA is thought to exert its neurotoxic effects through endothelial damage.
Arterial hypertension and chronic renal insufficiency act as additive factors. 31 The median age of these patients was approximately 2 decades above those transplanted for hematologic malignancies. Advanced age, which is associated with higher comorbidity and also with an elevated risk for GvHD, 32 and the rapid withdrawal of immunosuppression and application of DLI probably predisposed patients to higher rates of adverse events.
Long-term data in responding patients are not available, because the median follow-up in all studies was short. Several of the responding patients in the literature had secondary tumor progression. One of our patients, who developed very good PR (Figure 2 ), has been followed for more than 15 months since maximum tumor response without progression.
A comparison of seven transplanted vs 22 nontransplanted patients in our study showed comparable survival at 1 year, but follow-up is short. None of the nontransplanted patients, however, had responded to further therapies and half of these patients have already died from PD.
In conclusion, chimerism conversion to CC and subsequent GvHD after NST in metastatic RCC seem to provoke a delayed antitumor effect in several studies including our own. Taking into consideration the limitations of statistical analysis with pooled data from heterogenous studies, available information as well as our own experiences are highly suggestive of a GvT effect in patients with advanced RCC. Transplant-related morbidity and mortality is substantial despite reduced intensity conditioning and remains a matter of concern. Open questions concern optimal conditioning regimen, GvHD prophylaxis and timing of DLI after NST. Predictive factors for tumor responses after NST are currently unknown. Careful patient selection and close surveillance after NST are mandatory in these patients, who should be treated in Table 4 Conditioning regimen, GvHD and nonrelapse mortality of 95 patients with metastatic RCC after NST clinical trials. Only larger controlled studies will clarify the role of NST in the treatment of metastatic RCC.
